ClinicalTrials.gg
CompletedNCT02247401Updated Jul 30, 2021Results posted

Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

A Phase 3 interventional study of 2 DAA and RBV in HCV, Hepatitis C Infection and Genotype 4, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-07-30.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.

Enrollment
50th of 174
160 · median 78
Started
2014
with 16 others
Phase 3
56 of 174
none open now
Registered
134th of 174
by date
Lead sponsor
16 of 174
AbbVie

Among the 174 studies testing ribavirin in Hepatitis C, this one is the 50th largest by enrollment, is one of 17 that started in 2014, is one of 56 in phase 3, and was the 134th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 174 studies testing ribavirin in Hepatitis C as a file.
02

Study summary

This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.

Read the detailed description

Non-cirrhotic subjects were directly enrolled into Arm A. Cirrhotic subjects were randomized to either Arm B (12 weeks of treatment) or Arm C (24 weeks of treatment).

03

Conditions studied

  • HCV
  • Hepatitis C Infection
  • Genotype 4

Keywords

  • Genotype 4
  • non-responder
  • treatment experienced
  • HCV
  • naive
  • relapser
  • hepatitis infection
  • compensated cirrhosis
  • hepatitis c
  • Cirrhosis
  • Egypt
  • null responder
  • partial responder
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic , genotype 4-infection (hepatitis C virus [HCV] ribonucleic acid [RNA] level greater than 1,000 IU/mL at Screening)
  • Subjects must meet one of the following:

    • Treatment-naive: Subject has never received antiviral treatment for HCV infection OR
    • Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegylated-interferon [pegIFN]/RBV);
  • Females must be , of non-child bearing potential or practicing specific forms of
  • In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver or Fibroscan
  • In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan with score less than or equal to 6 at Screening and confirmed absence of hepatocellular carcinoma

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or breastfeeding
  • Positive screen for Surface antigen or anti- antibody
  • genotype performed during screening indicating unable to genotype or co-infection with any other HCV genotype
  • abnormal laboratory tests
  • self-reports current drinking more than 2 drinks per day
  • current enrollment in another study
  • previous treatment with a direct acting antiviral agent (DAA) containing regimen
  • In substudy 1, evidence of liver cirrhosis
  • In substudy 2, evidence of current or past B or C classification and confirmed presence of hepatocellular carcinoma
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Active comparator
    Arm A

    ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent \[DAA\]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.

    Drug: 2 DAA · Drug: RBV

  • Active comparator
    Arm B

    ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.

    Drug: 2 DAA · Drug: RBV

  • Active comparator
    Arm C

    ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.

    Drug: 2 DAA · Drug: RBV

Interventions

  • Drug2 DAA

    ABT-450/r/ABT-267 tablets

  • DrugRBV

    Ribavirin tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm

    SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\< LLOQ) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after last dose

  2. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.

    Time frame: Screening until 30 days after last dose

Secondary outcomes

  1. Percentage of Participants With On-treatment Virologic Failure in Each Treatment Arm

    On-treatment virologic failure was defined as quantifiable HCV RNA throughout the entire treatment period with at least 6 weeks of treatment, confirmed HCV RNA greater than the LLOQ after previously having unquantifiable HCV RNA, or a confirmed increase from nadir of at least one log10 in HCV RNA during treatment.

    Time frame: Up to 12 or 24 weeks after first dose

  2. Percentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment in Each Arm

    Post-treatment relapse was defined as defined as confirmed HCV RNA \> LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.

    Time frame: Up to 12 weeks after first dose

07

Results

Posted Jul 27, 2017

Participant flow

Safety population: All participants who received at least one dose of study drug.

Participant flow — Overall Study
MilestoneArm AArm BArm C
Started1003129
Completed942927
Not completed622
Withdrew: Adverse event100
Withdrew: Withdrawal by subject411
Withdrew: Lost to follow-up111

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm

SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\< LLOQ) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after last dose
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm
percentage of participantsArm AArm BArm C
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm94.0 (87.5 to 97.2)96.8 (83.8 to 99.4)93.1 (78.0 to 98.1)
PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.

Time frame:
Screening until 30 days after last dose
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsArm AArm BArm C
Number of Participants With Adverse Events802625
SecondaryPercentage of Participants With On-treatment Virologic Failure in Each Treatment Arm

On-treatment virologic failure was defined as quantifiable HCV RNA throughout the entire treatment period with at least 6 weeks of treatment, confirmed HCV RNA greater than the LLOQ after previously having unquantifiable HCV RNA, or a confirmed increase from nadir of at least one log10 in HCV RNA during treatment.

Time frame:
Up to 12 or 24 weeks after first dose
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure in Each Treatment Arm
percentage of participantsArm AArm BArm C
Percentage of Participants With On-treatment Virologic Failure in Each Treatment Arm1.0 (0.2 to 5.4)3.2 (0.6 to 16.2)3.4 (0.6 to 17.2)
SecondaryPercentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment in Each Arm

Post-treatment relapse was defined as defined as confirmed HCV RNA \> LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.

Time frame:
Up to 12 weeks after first dose
Reported as:
Number · percentage of participants
Percentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment in Each Arm
percentage of participantsArm AArm BArm C
Percentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment in Each Arm3.1 (1.0 to 8.6)0.0 (0.0 to 11.4)0.0 (0.0 to 12.1)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 30 days after the last dose of study drug (up to 28 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A—2/100 (2%)79/100 (79%)
Arm B—0/31 (0%)24/31 (77.4%)
Arm C—2/29 (6.9%)25/29 (86.2%)
Most frequent serious events
Most frequent serious events
EventArm AArm BArm C
OESOPHAGEAL VARICES HAEMORRHAGEGastrointestinal disorders0/1000/311/29
BILE DUCT STONEHepatobiliary disorders0/1000/311/29
CHOLECYSTITIS ACUTEHepatobiliary disorders0/1000/311/29
APNOEARespiratory, thoracic and mediastinal disorders1/1000/310/29
DEEP VEIN THROMBOSISVascular disorders1/1000/310/29
Most frequent other events
Showing 10 of 37
Most frequent other events
EventArm AArm BArm C
HEADACHENervous system disorders41/1009/3110/29
FATIGUEGeneral disorders35/1009/3111/29
COUGHRespiratory, thoracic and mediastinal disorders6/1004/319/29
PRURITUSSkin and subcutaneous tissue disorders23/1004/319/29
ABDOMINAL PAIN UPPERGastrointestinal disorders19/1002/313/29
DYSPEPSIAGastrointestinal disorders17/1004/315/29
NAUSEAGastrointestinal disorders7/1002/315/29
INSOMNIAPsychiatric disorders9/1002/315/29
CHROMATURIARenal and urinary disorders1/1000/315/29
ANAEMIABlood and lymphatic system disorders8/1002/314/29

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm AArm BArm CTotal
Mean48.6 ± 13.1457.3 ± 6.4855.8 ± 8.0251.6 ± 11.91
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BArm CTotal
Female302739
Male702922121
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):36-44. doi: 10.1016/S2468-1253(16)30002-4. Epub 2016 Jun 16. Erratum In: Lancet Gastroenterol Hepatol. 2016 Sep;1(1):e1. doi: 10.1016/S2468-1253(16)30039-5. PubMed 28404110 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2014
First posted
Sep 25, 2014
Start
Nov 4, 2014
Primary completionActual
Aug 1, 2016
CompletionActual
Aug 1, 2016
Results first posted
Jul 27, 2017
Last update
Jul 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02247401
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Nov 4, 2014
Primary completion
Aug 1, 2016
Completion
Aug 1, 2016
Results posted
Jul 27, 2017
Last update
Jul 30, 2021

Study contacts

Sarah Kopecky-Bromberg, PhD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribavirin

Start the discussion